Merck KGaA, Darmstadt, Germany , a leading science and technology company, today announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the ...
DARMSTADT, Germany, Jan. 20, 2021 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果